🔎 Trials Near Me

Hjem › Brystkreft › California › Irvine

Kliniske studier for Brystkreft i Irvine, CA

23 studier for Brystkreft søker deltakere på steder i og rundt Irvine (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

RekruttererFase 2
  • City of Hope at Irvine Lennar, Irvine
Alder 70 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT04305834

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

RekruttererFase 2
  • City of Hope at Orange County Lennar Foundation Cancer Center, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06369285

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

RekruttererFase 3
  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
  • City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

RekruttererFase 2
  • City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Alder 18 og eldre · Kvinner · Oppdatert 22. sep. 2026 · NCT07287098

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

RekruttererFrivillige helsepersonell ønskes velkommen
  • University of California Irvine, Irvine
Alder 30 til 74 · Kvinner · Oppdatert 21. sep. 2026 · NCT02620852

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

RekruttererFase 1/2
  • City of Hope, Irvine, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07109726

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

RekruttererFase 3
  • City of Hope at Irvine Lennar, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT06492616

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

RekruttererFase 1/2
  • City of Hope - Orange County Lennar Foundation Cancer Center, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT03424005

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

RekruttererFase 1/2
  • City of Hope, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT05315700

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

RekruttererFase 3
  • Hoag Hospital Center, Irvine
  • Hoag Hospital Irvine, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06072612

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

RekruttererFase 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • Kaiser Permanente-Irvine, Irvine
Alder 18 til 60 · Kvinner · Oppdatert 2. sep. 2026 · NCT05879926

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

Rekrutterer
  • City of Hope at Irvine Lennar, Irvine
Alder 18 og eldre · Kvinner · Oppdatert 10. aug. 2026 · NCT07741968

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

RekruttererFase 3
  • City of Hope - Orange County Lennar Foundation Cancer Center, Irvine
Alder 18 til 100 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT05232916

E-Mindfulness Approaches for Living After Breast Cancer

RekruttererFase 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • Kaiser Permanente-Irvine, Irvine
Alder 18 til 50 · Alle kjønn · Oppdatert 4. aug. 2026 · NCT06748222

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

RekruttererFase 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Alder 50 til 70 · Alle kjønn · Oppdatert 23. apr. 2026 · NCT04852887

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

RekruttererFase 2
  • City of Hope at Irvine Lennar, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 8. des. 2025 · NCT06910761

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

RekruttererFase 2
  • City of Hope at Irvine Lennar, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 5. des. 2025 · NCT06731894

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

RekruttererFase 2
  • City of Hope at Irvine Lennar, Irvine
Alder 40 og eldre · Kvinner · Oppdatert 29. okt. 2025 · NCT06954831

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RekruttererObservasjonsstudie
  • Massive Bio SYNERGY-AI site, Irvine
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

RekruttererFase 2
  • City of Hope at Irvine Lennar, Irvine
Alder 18 og eldre · Alle kjønn · Oppdatert 6. okt. 2025 · NCT06260033

Brystkreft-studier i andre byer

Andre studier i Irvine

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.